Multitumor | Virtual Molecular Tumor Board: Recognition and Management of Targetable Tumor Mutations in Less Common Cancer Types

Research To Practice | Oncology Videos

Proceedings from the third in a 3-part webinar series. Featuring perspectives from Drs Marcia S Brose, Andrew McKenzie and Milan Radovich, including on the following topics:

• Part 1: Molecular Tumor Board
• • Introduction (00:00)
  • Case: A woman in her late 70s with ER-positive, HER2-negative metastatic breast cancer (ESR, CHEK2 and RET mutations) — Sulfi Ibrahim, MD (6:09)
  • Case: A woman in her mid-40s with metastatic thymoma (MTOR gain-of-function mutation) — Milan Radovich, PhD (13:29)
  • Case: A patient with leiomyosarcoma (BRCA germline mutation) — Andrew McKenzie, PhD (15:05)
  • Case: A patient with bone-only disease — Dr Ibrahim (16:44)
• Part 2: New Molecular Targets in Thyroid Cancer
• • Case: A woman in her late 30s with RAI-refractory papillary thyroid cancer — Marcia S Brose, MD, PhD (21:25)
  • Case: A man in his late 60s with papillary thyroid cancer — Dr Brose (29:25)
  • Case: A woman in her late teens with locally advanced medullary thyroid cancer — Dr Brose (36:04)
  • Case: A frail woman in her late 70s with metastatic papillary thyroid cancer (CAD) — Dr Ibrahim (39:46)
  • Case: A man in his late 50s with metastatic thyroid cancer (RET M918T gain-of-function mutation) — Dr Radovich (43:40)
  • Case: A man in his early 70s with metastatic medullary thyroid cancer (RET mutation) — Dr McKenzie (46:27)
• Part 3: Targeting the FGFR Signaling Pathway in Cholangiocarcinoma
• • Case: A woman in her late 50s with metastatic cholangiocarcinoma (FGFR2-BICC1 fusion) — Dr Radovich (48:28)
• Part 4: New Options in the Management of GIST Harboring PDGFR Mutations
• • Case: A patient with GIST (PDGFRA) — Dr McKenzie (52:57)
  • Case: A woman in her early 60s with metastatic GIST (gain-of-function PDGFRA D842Y mutation) — Dr Radovich (54:23)
• Part 5: Molecular Tumor Board (Continued)
• • Case: A man in his late 70s with metastatic pancreatic cancer (EGFR exon 19 deletion) — Justin Peter Favaro, MD, PhD (55:30)

CME information and select publications